Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of MK-7240 in moderately to severely active ulcerative colitis
MOH_2023-11-20_013063Phase 3Recruiting
- Sponsor
- Merck & Co.
- Start
- Nov 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tulisokibart in autoimmune colitis (7 arms), sponsored by Merck & Co. Started Nov 2023; status: recruiting.
02
Drugs
tulisokibart
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on MOH_2023-11-20_013063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-11-20_013063.